Leading contract research, development and manufacturing organisation Syngene International (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is participating as exhibitor at the Bio International Convention, San Diego, between 3-6 June 2024.
Syngene is set to showcase its robust suite of services, which are designed to accelerate biologics from discovery to market with industry-leading speed and efficiency. Offering end-to-end services from discovery and development through to clinical and commercial supplies, Syngene possesses a wide range of experience with various molecule types, including antibodies, ADCs, fusion proteins, mRNA, pDNA, VLPs, multimeric protein complexes, and vaccines.
Syngene recently acquired a cGMP manufacturing facility to serve biotech and pharma customers in need of drug substance and drug product contract manufacturing. With two production suites equipped with multiple 2KL single-use bioreactors, two high-speed vial filling lines capable of filling up to one million vials a day, and a development suite equipped with a 500l single-use bioreactor for the clinical supply of drug substance, Syngene provides unparalleled service. This facility has significantly amplified Syngene’s bio-manufacturing capacity, supplementing its existing commercial manufacturing site in Bangalore, India – BMP 1, and its PROTAC research site in Hyderabad, India. Both sites are approved by top regulatory bodies such as the US FDA, with no 483 observations, and the EMA.
Syngene also has a microbial manufacturing facility of up to 500L scale along with a comprehensive array of preclinical solutions, including analytical, viral clearance, and viral testing solutions.
Visit Syngene at Exhibition Hall 5757 to explore how they can assist with your biologics development and manufacturing challenges, enabling and accelerating your innovation journey.
About Bio International Convention 2024
BIO 2024, where issues and insights converge, offers more than 100 sessions across 18 focus areas, featuring discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates who are committed to groundbreaking therapies and innovation.